By combining an FDA-approved cancer immunotherapy with an emerging nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice. The potent combination completely cured two mice and effectively vaccinated one against the cancer.

See the source article by following the link below:
By combining an FDA-approved cancer immunotherapy with an emerging nanotechnology, Duke University researchers improved the efficacy of both therapies in a proof-of-concept study using mice. The potent combination completely cured two mice and effectively vaccinated one against the cancer.